LONDON, United Kingdom, March 13, 2026
Global biopharmaceutical company GSK has announced that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of its respiratory syncytial virus (RSV) vaccine, Arexvy, allowing its use in adults aged 18 to 49 years who are at increased risk of RSV-related lower respiratory tract disease (LRTD). The regulatory decision marks a significant milestone in adult RSV prevention, broadening protection to younger adults with chronic medical conditions who are vulnerable to severe respiratory infections. The expanded approval reflects strong clinical evidence demonstrating immune response and safety comparable to older adult populations, reinforcing the vaccine’s role in addressing a major global infectious disease burden.
FDA Expands RSV Vaccine Protection to Younger Adults
The FDA’s approval expands the label of Arexvy, which was previously authorized for the prevention of RSV-related lower respiratory tract disease in adults aged 60 years and older and adults aged 50–59 with increased risk factors. With the latest regulatory decision, adults aged 18–49 with underlying health conditions such as chronic cardiopulmonary disease, diabetes, kidney disease, or obesity can now receive the vaccine to protect against severe RSV complications.
Respiratory syncytial virus is a highly contagious respiratory pathogen that infects millions of people worldwide each year, causing illnesses ranging from mild cold-like symptoms to severe pneumonia and hospitalization. Although RSV is commonly associated with infants and older adults, younger adults with chronic health conditions face a significantly elevated risk of severe disease.
In the United States alone, an estimated 21 million adults under the age of 50 have at least one risk factor associated with severe RSV infection, contributing to a substantial healthcare burden. Epidemiological data indicate that RSV leads to approximately 17,000 hospitalizations, 277,000 emergency department visits, and nearly two million outpatient visits annually among adults aged 18–49. By expanding vaccination eligibility, health authorities aim to reduce hospitalizations, ease pressure on healthcare systems, and improve prevention strategies for respiratory infections.
Advertisement
Phase III Clinical Evidence Supports Regulatory Approval
The FDA’s decision was supported by data from a Phase IIIb clinical trial evaluating the immunogenicity and safety of the RSV vaccine in adults aged 18–49 at increased risk of severe disease. The study enrolled 1,458 participants across 52 clinical sites in six countries, including 16 sites in the United States, and assessed immune responses after a single dose of the vaccine.
The primary objective of the trial was to demonstrate that the immune response generated in adults aged 18–49 was non-inferior to the immune response observed in adults aged 60 years and older, a population already approved for vaccination. Results confirmed that neutralizing antibody responses against RSV-A and RSV-B were comparable between both groups, providing strong evidence supporting the vaccine’s effectiveness in younger high-risk adults.
Safety outcomes observed during the study were consistent with earlier Phase III clinical trials that supported the initial approval of Arexvy. The most commonly reported adverse events included injection site pain, fatigue, muscle pain, headache, and joint discomfort, which were generally mild to moderate and resolved within a few days after vaccination. These findings reinforce the vaccine’s favorable safety and tolerability profile, an important consideration for broader immunization programs.
Expanding Global RSV Prevention Strategy
The expanded approval represents an important step in GSK’s global strategy to combat respiratory infectious diseases through advanced vaccine development. The RSV vaccine contains a recombinant RSV prefusion F glycoprotein antigen combined with the AS01E adjuvant system, designed to enhance immune responses and provide durable protection against RSV infection.
Currently, Arexvy is approved in more than 70 countries for adults aged 60 years and older, and in over 60 countries for adults aged 50–59 with underlying health conditions. In the European Economic Area, regulatory authorities have already approved the vaccine for all adults aged 18 years and older, reflecting increasing global recognition of the need for broader RSV protection.
RSV remains a major public health challenge, infecting an estimated 64 million people globally each year and contributing to significant healthcare costs and complications, particularly in high-risk populations. Adults hospitalized with RSV often face serious complications such as pneumonia, exacerbation of chronic respiratory diseases, and prolonged hospital stays, underscoring the importance of preventive vaccination strategies.
By expanding vaccine eligibility to younger high-risk adults, public health experts believe vaccination programs can significantly reduce severe RSV outcomes and improve respiratory disease prevention worldwide. As regulatory approvals expand and immunization programs evolve, Arexvy is expected to play a central role in protecting vulnerable populations against one of the most common respiratory viruses affecting adults globally.
Source: GSK press release
